XML 24 R8.htm IDEA: XBRL DOCUMENT v3.24.0.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2023
Dec. 31, 2022
Cash flows used in operating activities:    
Net loss $ (614,928) $ (78,782)
Adjustments to reconcile net loss to net cash used in operating activities:    
Gain on remeasurement of liabilities 0 (1,265)
Non-cash interest expense 6,253 4,303
Amortization of discount on short-term investments (1,924) 0
Unrealized foreign currency (gain) loss (812) 2,616
Reclassification of currency translation gain (419) 0
Impairment of fixed assets 474 0
Amortization of operating right-of-use assets 1,852 1,251
Depreciation 198 349
Amortization of intangible assets 0 914
Impairment of intangible assets 0 8,468
Stock-based compensation 14,108 11,948
Loss on disposal of assets (109) 0
In-process research and development expense 520,915 0
Changes in operating assets and liabilities:    
Accounts receivable 359 975
Prepaid expenses (914) 5,107
Other current and long-term assets (3,421) 215
Research and development tax credit receivable 4,168 8,437
Deferred revenue and other income 0 (7,278)
Accounts payable 2,263 (4,132)
Accrued liabilities (2,377) 4,782
Accrued compensation (235) 1,609
Operating lease liabilities (2,211) (1,099)
Net cash used in operating activities (76,760) (41,582)
Cash flows used in investing activities:    
Purchase of property and equipment (128) (624)
Proceeds from sale of property. plant and equipment 226 0
Purchase of short-term investments (321,022) 0
Maturities and sales of short-term investments 208,165 0
Payments to Akeso for upfront milestone payments and associated direct transaction costs (475,015) 0
Net cash used in investing activities (587,774) (624)
Cash flows provided by financing activities:    
Proceeds from the issuance of common stock for rights offering 104,686 100,000
Transaction costs from the issuance of common stock for rights offering (619) (111)
Proceeds from the issuance of common stock via private placement 5,000 0
Net receipts related to the exercise of warrants 1,203 0
Proceeds received related to employee stock purchase plan and exercise of stock options 929 399
Proceeds from related party promissory notes 0 545,000
Re-payment of related party promissory notes (24,686) (25,000)
Payments of related party promissory notes issuance costs 0 (44)
Net cash provided by financing activities 86,513 620,244
Effect of exchange rates on cash and cash equivalents 839 (1,222)
(Decrease) Increase in cash, cash equivalents and restricted cash (577,182) 576,816
Cash, cash equivalents and restricted cash at beginning of period 648,607 71,791
Cash, cash equivalents and restricted cash at end of period 71,425 648,607
Cash paid for interest on related party promissory note 10,650 434
Cash paid for income taxes 52 0
Debt issuance costs in accrued expenses 0 31
Deferred transaction costs included in other non-current assets 0 425
Leased assets obtained in exchange for operating lease liabilities 4,245 2,860
Akeso License Agreement    
Issuance of common stock 45,900 0
Rights Offering    
Issuance of common stock $ 395,314 $ 0